Ankit Kansagra, MD, an assistant professor in theDepartment of Internal Medicineat UT Southwestern Medical Center and assistant director of theOutpatient Stem Cell Transplant Program, discusses chimeric antigen receptor T-cell agents in the pipeline for multiple myeloma (MM) and how these therapies may impact the treatment landscape pending future approvals.
In part two of this interview with Dr. Kansagra, available December X, he discusses potential new combination therapy options for MM.
DocWire News: Dr. Kansagra, can you discuss some of the CAR T-cell therapies in development for multiple myeloma, including their targets, clinical trial data that weve seen, and your expectations for any future FDA approvals?
Dr. Kansagra: In multiple myeloma, a few of the CAR T-cell therapy targets, which in the most developments, have been the BCMA-targeted CAR T-cell therapies. Those have been most exciting because they have made it to the phase I to phase II trials, especially the registrational studies from Celgene or Bluebird, BMS, the bb2121 compound or the Janssen compound 4538, being farthest out in the clinical development for CAR T-cell therapy. There are certainly a few other CAR T-cell therapies for multiple myeloma, which have grown, and theyre probably in the earlier development of therapy. An example being the CD38 CAR T-cell therapy, the SLAMF CAR T-cell therapy, and GPR5CD CAR T-cell therapy. Those are the three different targets which are being evaluated as T-cell targets.
DocWire News: How do you see the approval of these CAR T-cell therapy impacting the treatment landscape for multiple myeloma?
Dr. Kansagra: I think its going to be a huge improvement in our momentum of our treatment options. We have already seen cell therapy in myeloma have impressive results in terms of the response rates. I think the first important step is you have these patients who have got six or seven different lines of treatment, and now they are getting a novel product or a novel mechanism of action and also novel target and seeing an impressive response rate. That was amazing. Thats step number one.
Step number two is, as we have got further into the clinical development of CAR T-cell therapy, we have seen the safety of these products because that is extremely important that our products are safer.
Then the third thing which we have seen is that long-term follow-ups are not there, but what we have started seeing is that our responses, which could last up to a year or a year and a half for the population, where we would have usually seen maybe barely a response in a matter of months.
I think those are exciting times for our patients with multiple myeloma, where they have failed a lot of therapies. I think the more exciting times are going to come when we will start seeing these CAR T-cell therapies, potentially even in earlier lines of treatment options, where they could use maybe as a second-line treatment or as a first-line treatment after stem cell transplant or in lieu of stem cell transplant, maybe we can have deeper and longer remission rates.
DocWire News: With some of these agents potentially coming to market, do you foresee any challenges, either associated with adverse events or the ability to make these treatments widely available to patients?
Dr. Kansagra: Access to care is certainly near and dear to me, and thinking about those challenges is extremely, extremely important. I think were going to probably face challenges in a lot of different ways.
The first thing is, obviously, how can we get our patients to the centers who are giving CAR T-cell therapy? How are we going to bring them? We know from our autologous stem cell transplant over the last three to four decades, that still not every eligible transplant patient is referred to a transplant center, for whatever reasons. There are multiple reasons; there are socioeconomic reasons; there are distance reasons. But a lot of them are fixable reasons. There are some which are unfixable, but there are some fixable. I think the first and the foremost important thing is going to be to get our patients to a place who is delivering CAR T-cell therapy. Thats the challenge number one.
Challenge number two is, once they are in there, making sure that they are able to get that thing. So it means theyre not coming too late in their game, so trying to make sure theyre referred in earlier points, so that processes in place, that insurance approval has got started, if we need to work on the sociodemographic issues, how are they going to stay in a particular area? What is the social help, what is the family help theyre going to need? If they had referred earlier on, thats another, I call it, bottleneck that we need to think of that. Thats where we need to act on it.
The hard thing is obviously the cost. We dont know what is going to be the cost of the myeloma CAR T-cell therapy, or what is the price of those things. We can certainly estimate that its not going to be as cheap given the three CAR-Ts, which are not FDA-approved. I think its going to be expensive. You will have to think of the cost of care model of how we are going to work with this.
Last but not least of the challenges are the CAR-T itself. These are in the logistical challenge bucket. Then there are the challenges in the CAR-T landscape or the product itself. We still know that these are second-generation CAR T-cell therapies. They dont work for everybody. They have a high response rates, but they dont last that long. We hope to see longer remissions. An example I give, in comparison to large-cell lymphoma, we had 50% of the people who plateaued out, now coming up to about three years. In myeloma, we havent obviously made it to three years since the CAR T-cell therapy have started, but we do worry that there is a tail end of the curve that people are already relapsing to it. Obviously, that goes to the product itself or the construct itself, which needs to be developed in multiple different ways. I think of them as two major challenges ahead of us.
Read the original post:
- BCH-BB694 Gene Therapy Safely Treating Severe SCD Patients in... - Sickle Cell Anemia News - January 17th, 2021
- Stem cells on the ballot - Science Magazine - January 16th, 2021
- Induction of muscle-regenerative multipotent stem cells from human adipocytes by PDGF-AB and 5-azacytidine - Science Advances - January 16th, 2021
- Eye stem cell transplant to treat blindness bolsters retinal function in monkeys - FierceBiotech - January 16th, 2021
- Stem cells with regenerative abilities could be closer on the horizon, shows study - News-Medical.net - January 16th, 2021
- Center for cell and gene therapy to open next year - Harvard Gazette - January 16th, 2021
- Study: Retinal stem cells from cadavers may help restore vision in blind - UPI News - January 16th, 2021
- Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by FDA for the Treatment of Metachromatic... - January 16th, 2021
- Bone Therapeutics and Rigenerand sign partnership for cell therapy process development - GlobeNewswire - January 16th, 2021
- Creative Medical Technology Holdings Files Investigational New Drug Application (IND) with FDA for Treatment of Stroke using ImmCelz Regenerative... - January 16th, 2021
- News briefing: Precision Medicine Group acquires cell and gene therapy-focused services firm Project Farma; RoosterBio and Sartorius collab on gene... - January 16th, 2021
- Mutations in Gene Linked to Acute Myeloid Leukemia Can Drive Other Blood Disorders - Clinical OMICs News - January 16th, 2021
- Regenerative Medicine Market to Reach Valuation US$ 23.7 Bn by 2027 - GlobeNewswire - January 10th, 2021
- Doctors Make Medical Breakthrough In Treating Severe Cases Of COVID - CBS Denver - January 10th, 2021
- Human Embryonic Stem Cell hESC Market is Booming Worldwide with Types of Players Like Astellas Institute of Regenerative Medicine (US), Asterias... - January 10th, 2021
- Chemicals in e-cigarettes disrupt the gut barrier and trigger inflammation - News-Medical.Net - January 10th, 2021
- Creative Medical Technology Holdings Announces Patent filing based on Preclinical Data in Model of Heart Attack using ImmCelz Regenerative... - January 3rd, 2021
- Creative Medical Technology Holdings Announces Reversion of Liver Failure Using ImmCelz Personalized Cellular Immunotherapy in Preclinical Model -... - December 30th, 2020
- ImmCelz, CaverStem, StemSpine; the Run on Creative Medical Technology Holdings Inc (OTCMKTS: CELZ) - MicroCap Daily - December 30th, 2020
- BCL11A Inhibition to Induce Fetal Hemoglobin Shows Promise in Sickle Cell Disease - Hematology Advisor - December 30th, 2020
- ViviGen Cellular Bone Matrix outperforms MSC-based allografts and is equivalent to gold standard autograft - PRNewswire - December 30th, 2020
- Study clarifies the effect of aging on hematopoietic stem cells - News-Medical.net - December 27th, 2020
- Modulating BST2 expression on blood stem cells may help regulate cell activation during chronic infections - News-Medical.Net - December 27th, 2020
- CAR T-Cell Therapies Are Set to Expand Into More Hematologic Malignancy Indications - Targeted Oncology - December 27th, 2020
- Post-doctoral Research Officer Job at Children's Medical Research Institute in Sydney, Australia - The Conversation AU - December 27th, 2020
- Six Benefits of All-on-4 Implants Compared to Regular Dentures - Magazine of Santa Clarita - December 27th, 2020
- Athersys (ATHX) and UTHealth Begin Patient Enrollment in Phase 2 Trial Evaluating MultiStem Cell Therapy in Trauma - StreetInsider.com - December 23rd, 2020
- Medicine by Design symposium highlights importance of convergence in regenerative medicine and human health - News@UofT - December 23rd, 2020
- Robert Gallo of the UM School of Medicine Institute of Human Virology and Global Virus Network Awarded Top Life Sciences and Medicine Prize from China... - December 23rd, 2020
- Leaders in stem cell science, regenerative medicine ... - December 18th, 2020
- Stem Cell & Regenerative Medicine Market By Covid-19 ... - December 18th, 2020
- Skandalaris LEAP winners announced | WashU Fuse | Washington University in St. Louis - Washington University in St. Louis Newsroom - December 18th, 2020
- Therapeutic Solutions International Files Investigational New Drug Application (IND) with FDA for Treatment of Chronic Traumatic Encephalopathy Using... - December 18th, 2020
- Physio Logic Brings Cutting-edge Regenerative Treatments for Sport Injuries and Arthritis to New York City - PRNewswire - December 18th, 2020
- Stem cells: Therapy, controversy, and research | Femto ... - December 18th, 2020
- Scientists use human stem cells and bioengineered scaffold to build whole functioning thymus - News-Medical.Net - December 15th, 2020
- Updated Findings Show Continued Efficacy for CAR T-Cell Therapy in Heavily Pretreated Myeloma - Targeted Oncology - December 15th, 2020
- CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV - BioSpace - December 15th, 2020
- CollPlant to Supply rhCollagen to STEMCELL Technologies for Use in a Broad Range of Cell Culture Applications - PRNewswire - December 15th, 2020
- Cell Isolation/ Separation Market worth $15.0 billion by 2025 - Exclusive Report by MarketsandMarkets - PRNewswire - December 15th, 2020
- Europe Tissue Engineering Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Material Type, Applications, and Country -... - December 7th, 2020
- Treatment with Investigational LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111) Results in Complete Elimination of SCD-Related Severe... - December 7th, 2020
- HSCT Found Potentially Curative for Some T-Cell Lymphoma Patients - Cancer Therapy Advisor - December 6th, 2020
- ASH Goes Remote as CAR T-Cell Therapy Competition Heats Up - AJMC.com Managed Markets Network - December 6th, 2020
- Gamida Cell Presents Updated, Expanded Results from Phase 1 Study of Natural Killer Cell Therapy GDA-201 at ASH Annual Meeting and Exposition -... - December 6th, 2020
- New Drug Could Improve Effectiveness of Stem Cell Therapy - Pain News Network - December 1st, 2020
- Hematologist/Stem Cell Biologist to Direct Hematology and Cellular Therapy at Cedars-Sinai - Newswise - December 1st, 2020
- Experimental stem cell gene therapy may give a new lease of life for patient with sickle cell disease - News-Medical.Net - December 1st, 2020
- Coronavirus Updates: The Latest Treatments and Vaccines - GovTech - December 1st, 2020
- ONLINE: The UW Now - Isthmus - December 1st, 2020
- Exploring the Challenges and Opportunities of Harvesting CTCs - Technology Networks - December 1st, 2020
- Mustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - GlobeNewswire - December 1st, 2020
- Celularity Announces Positive DMC Safety Review and Continuation of its Phase I/II CYNK-001-COVID-19 (CYNKCOVID) Study - PRNewswire - December 1st, 2020
- COVID-19 patients on some cancer therapies may be contagious for months: study - Reuters - December 1st, 2020
- Gain Therapeutics and University of Maryland School of Medicine Announce Research Collaboration - GlobeNewswire - December 1st, 2020
- Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine - GlobeNewswire - November 30th, 2020
- Coronavirus treatments and vaccines. Here are the latest developments - San Francisco Chronicle - November 30th, 2020
- Stem Cell Assay Market Research Report: Industrial Chain, Sourcing Strategy and Downstream Buyers with Forecast 2026 - Cheshire Media - November 30th, 2020
- Human Embryonic Stem Cell (hESC) Market Research Report 2020 with Manufacturing Process Analysis and Market Concentration Rate till 2026 - The Market... - November 30th, 2020
- Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes - Philippine Canadian... - November 30th, 2020
- California's stem cell research agency looks to the future - Bond Buyer - November 26th, 2020
- Scientists Reveal a New Drug That Directs Stem Cells To Desired Sites - Science Times - November 26th, 2020
- Growing Value of Stem Cells in Medicine to Create a US$2,4 Billion Opportunity for Induced Pluripotent Stem Cell ((iPSC) - GlobeNewswire - November 26th, 2020
- Celularity Announces Dosing of First Patient in Phase I Study of Human Placental Hematopoietic Stem Cell-Derived Natural Killer Cells (CYNK-001) in... - November 26th, 2020
- Unexpected discovery about stem cell immortality study - News - The University of Sydney - November 26th, 2020
- 'The hope is that is works': Coliseum participates in clinical trial for COVID-19 recovery - wgxa.tv - November 26th, 2020
- Growing at an annualized rate of over 16.5%, the cell therapy manufacturing market is estimated to reach close to USD 11 Billion by 2030, claims Roots... - November 26th, 2020
- Global Cell Harvesting Market to Reach US$381,4 Million by the Year 2027 - PRNewswire - November 26th, 2020
- Novel CAR T-cell therapy shows promising early results in children with neuroblastoma - News-Medical.Net - November 26th, 2020
- Our turbulent debates on medicine and morals - The Irish Catholic - November 26th, 2020
- Impact of COVID 19 on Orthopedic Regenerative Medicine Market Detailed Research Study 2020-2027 | Curasan, Inc., Carmell Therapeutics Corporation,... - November 26th, 2020
- Novartis Invests in Stem Cell Therapy for Covid - BloombergQuint - November 20th, 2020
- California's Stem Cell Agency Will Get A Funding Boost From Prop 14. Here's A Look At Its History. - Capital Public Radio News - November 20th, 2020
- Fred Hutch at ASH: Fauci fireside chat, latest on cell therapies, repairing immune function, COVID and clots and more - Newswise - November 20th, 2020
- Study reveals how smoking worsens SARS-CoV-2 infection in the airways - UCLA Newsroom - November 20th, 2020
- SEE | Smoking worsens Covid-19 infection in the airways, new study reveals - Health24 - November 20th, 2020
- In a First, Scientists Say They've Partially Reversed a Cellular Aging Process in Humans - ScienceAlert - November 20th, 2020
- ExCellThera to establish stem cell bioproduction facility creating up to 150 jobs thanks to Government of Canada support - Canada NewsWire - November 16th, 2020
- Stanford coach's quest to save his brother: 'God, I hope this works' - Scope - November 16th, 2020
- Athersys Announces Three Appointments to Board of Directors - Business Wire - November 16th, 2020